CoChat

Tau as a therapeutic target in neurodegenerative disease

Open access
Himmelstein, Diana S., Ward, Sarah M., Lancia, Jody K., Patterson, Kristina R., Binder, Lester I. · 2012 · Pharmacology & Therapeutics
Cited by 115

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Tau is a microtubule-associated protein thought to help modulate the stability of neuronal microtubules. In tauopathies, including Alzheimer’s disease and several frontotemporal dementias, tau is abnormally modified and misfolded resulting in its disassociation from microtubules and the generation of pathological lesions characteristic for each disease. A recent surge in the population of people with neurodegenerative tauopathies has highlighted the immense need for disease-modifying therapies for these conditions, and new attention has focused on tau as a potential target for intervention. In the current work we summarize evidence linking tau to disease pathogenesis and review recent therapeutic approaches aimed at ameliorating tau dysfunction. The primary therapeutic tactics considered include kinase inhibitors and phosphatase activators, immunotherapies, small molecule inhibitors of protein aggregation, and microtubule-stabilizing agents. Although the evidence for tau-based treatments is encouraging, additional work is undoubtedly needed to optimize each treatment strategy for the successful development of safe and effective therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2012.07.001

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 115

Metadata

Authors
Himmelstein, D. S., Ward, S. M., Lancia, J. K., Patterson, K. R., & Binder, L. I.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2012-10
Volume
136
Issue
1
Pages
8-22
ISSN
0163-7258 (ISSN-L)
OpenAlex
W2032643430
Cited by
115
References
50
FWCI
6.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tau as a therapeutic target in neurodegenerative disease. https://app.cochat.ai/papers/10.1016/j.pharmthera.2012.07.001
The paper
Himmelstein, D. S., Ward, S. M., Lancia, J. K., Patterson, K. R., & Binder, L. I. (2012). Tau as a therapeutic target in neurodegenerative disease. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2012.07.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.